In October 2021, Vaxxinova acquired Newport Laboratories (Worthington, MN), having previously acquired Epitopix (Willmar, MN) in April of 2018.  Now in August 2023, our two US businesses will begin re-branding our company as a single entity, Vaxxinova US. Rest assured that Newport Labs is and will remain a critical brand of Vaxxinova.

As Vaxxinova, we will remain committed to serving our customers by providing high quality products and diagnostics, supported by our global R&D network. We continue to develop a diversified vaccine portfolio against many pathogens, and superior customer service including the new “MyVaxx” digital portal to help you track your custom-made vaccines.

For more information, please reach out to your Vaxxinova representative or call us at 800-220-2522.